FDA Greenlights Generics for Gallstone Drug After Safety Check
Published Date: 5/30/2025
Notice
Summary
The FDA says ACTIGALL 150 mg capsules weren’t pulled from the market because of safety or effectiveness problems. This means drug companies can now get approval to make and sell generic versions of this medicine, as long as they follow the rules. Patients and pharmacies can expect more affordable options soon without any safety worries!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
FDA OKs Pathway for Generics
The FDA determined that ACTIGALL (ursodiol) capsule, 150 milligrams, was not withdrawn from sale for reasons of safety or effectiveness. Because of that determination, the FDA can approve abbreviated new drug applications (ANDAs) for ursodiol 150 mg if all other legal and regulatory requirements are met.
More Affordable Options Expected
The notice says patients and pharmacies can expect more affordable options for ACTIGALL (ursodiol) 150 mg because the FDA can now approve generic versions, and the agency found no safety or effectiveness reason the branded product was withdrawn.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-09778, 60-Day Notice of Proposed Information Collection: Special Immigrant Visa Biodata Form
The Department of State wants to update the Special Immigrant Visa Biodata Form and needs your feedback before making changes official. This affects people applying for special immigrant visas and helps keep the form clear and easy to use. You’ve got 60 days to share your thoughts—no extra costs, just your voice!
Next: 2025-09780, Agency Information Collection Proposed Extension
The Energy Information Administration (EIA) wants to keep collecting important info on natural gas liquids and oil and gas reserves for three more years, with some updates to the forms. They’re also keeping one survey paused for now. If you’re involved in the energy industry, this affects you, and the EIA is asking for your thoughts before moving forward—so don’t miss the chance to weigh in!